Abstract Antibody-drug conjugates (ADCs) have transformed the landscape of modern drug development, offering a powerful way to deliver chemotherapy with precision. But translating an ADC concept into a successful candidate requires an integrated approach to identify targets, optimize payload delivery directly to the tumor, and validate efficacy across ex vivo and in vivo preclinical models. The challenge remains to develop improved preclinical tools and select the right pipeline supporting ADC development that will be more predictive of clinical outcome. Oncodesign Services has generated a comprehensive preclinical platform to support ADC functional characterization by integrating in vitro binding and internalization assays to pharmacokinetics, pharmacodynamics along with efficacy studies in translational models. We offer a wide range of specialized assays and validation tools that examine both antibody and target characterization including a wide range of biological activity (MoA) functional cell-based assays. Available assays include target binding, ADC internalization, payload function and tumor cell kill potency, while available organoid platforms for enhanced translational relevance. Oncodesign Services includes over 500 tumor models across 35 cancer indications, offering a wide selection of translational models to support your efficacy studies, including patient-derived xenografts (PDX) as well as syngeneic and humanized models. In this poster we show different pre-clinical experiments steps including cellular assays, relevant in vivo models tested with FDA approved ADC payloads in validated target expression tumor combined with imaging technologies and radiopharmaceutical ADCs. The application of preclinical molecular imaging techniques by conjugating an ADC to a fluorescent tag or radioactively labeled improve the identification of effective candidate ADC molecules for therapeutic success. From concept to proof-of-efficacy, Oncodesign Services present a platform combining biological and pharmacological expertise to accelerate the identification of effective candidate ADC molecules with the best chance of clinical translation and cancer patient benefit. Citation Format: Ismahène Benzaid, Peggy Provent, Aurélie Durgeau, Didier Grillot, Marc Hillairet de Boisferon. An integrate comprehensive in vitro and in vivo strategies for antibody drug conjugate development abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1706.
Benzaïd et al. (2026) studied this question.